Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:02am, Thursday, 30'th Jul 2026
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates
10:36am, Thursday, 30'th Jul 2026
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.84 per share, missing the Zacks Consensus Estimate of $2.05 per share. This compares to earnings of $0.32 per share a year ago.
Alnylam Pharmaceuticals Q2 Earnings Call Highlights
10:06am, Thursday, 30'th Jul 2026
Alnylam Pharmaceuticals NASDAQ: ALNY reported second-quarter 2026 global net product revenue of approximately $1.2 billion, up 74% from a year earlier, driven by continued uptake of AMVUTTRA for trans
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
08:00am, Thursday, 30'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics
10:15am, Tuesday, 28'th Jul 2026
Beyond analysts' top-and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Dimensional Fund Advisors LP Purchases 82,340 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
03:17am, Tuesday, 28'th Jul 2026
Dimensional Fund Advisors LP raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 27.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 384
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Thursday, 23'rd Jul 2026
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Andra AP fonden Raises Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
03:19am, Tuesday, 21'st Jul 2026
Andra AP fonden increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 78.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities a
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Lifted by Fifth Third Bancorp
04:30am, Monday, 20'th Jul 2026
Fifth Third Bancorp grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 7,433.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commiss
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Allspring Global Investments Holdings LLC
03:08am, Saturday, 18'th Jul 2026
Allspring Global Investments Holdings LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 1.1% in the undefined quarter, according to its most recent filing with the SEC. The firm ow
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
08:00am, Thursday, 16'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
05:44am, Thursday, 16'th Jul 2026
I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
03:30am, Wednesday, 15'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
12:25pm, Monday, 13'th Jul 2026
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
11:35am, Thursday, 09'th Jul 2026
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
